Flagship Pioneering and Quotient Therapeutics Partner with Pfizer to Advance Research in Cardiovascular and Renal Diseases
Flagship Pioneering and its subsidiary Quotient Therapeutics have announced a new research initiative under their strategic partnership with Pfizer to identify potential therapeutic targets for cardiovascular and renal diseases. This collaboration leverages Quotient's Somatic Genomics platform to study somatic mutations in patient tissues, which may play a role in the progression of these diseases.
Quotient Therapeutics, founded by Flagship Pioneering in 2022, focuses on the genetic diversity within the human body’s cells to discover novel disease-related gene links. The company's platform will be used to explore the genetic variations that could provide new insights into cardiovascular and renal disease mechanisms, potentially leading to innovative treatments.
The research initiative will be carried out in collaboration with Pioneering Medicines, Flagship's in-house drug development unit, which leads strategic partnerships, including the one with Pfizer established in July 2023. The goal of this alliance is to accelerate the discovery and development of new therapies for conditions with significant unmet medical needs.
Pfizer's involvement brings its extensive experience in cardiovascular and renal research to the partnership. According to Bill Sessa, Chief Scientific Officer of Pfizer's Internal Medicine Research Unit, the collaboration aims to utilize Quotient’s proprietary platform to uncover new therapeutic targets, building on Pfizer's existing cardiometabolic expertise.
Topics: Startups & Deals
